BioElectronics Company Updates
Thursday, July 2, 2015
ActiPatch One-Year Pain Management Assessment
BioElectronics has set up a trial program in the United Kingdom and Ireland where interested parties sign up for a 7-day (use time) ActiPatch® Therapy device. The commercial ActiPatch® Therapy device has a 30-day use time. The 7-Day trial program started over a year ago and data is now being collected from consumers after a year of ActiPatch use. We follow up with a 30-day, 90-day and have just started the one-year surveys. The preliminary clinical data shows that the long term benefit of ActiPatch is sustained at the 1-year time point, with an average 54% decrease in pain, and with the vast majority of users (85%) indicating that they will continue to use ActiPatch in the future. With average consumer use being 2.7 devices over the year. This data is the first data confirming that we a building a sound, long term consumer base with the ongoing 7 Day trial device program.
BioElectronics Social Media
Next Company Update: Thursday, August 6, 2015
To receive investor updates via e-mail, please contact us at IR@bielcorp.com with your name and e-mail address. Updates are posted every other Thursday. Thank you for your support!